Radioprotective effect of montelukast sodium against hepatic radioiodine (131I) toxicity: A histopathological investigation in the rat model

Abstract

Summary: Radioactive iodine (131 I) is a known radionuclide which is used both for diagnostic and therapeutic purposes in the treatment of hyperthyroidism and thyroid cancer. Montelukast sodium (Cysteinyl leukotriene receptor-1 antagonist) is also a wellknown antioxidant drug. This study aimed to evaluate the histopathological changes in rat livers at the third month following 131 I treatment and the radioprotective effect of Montelukast sodium (ML) against 131 I-related liver damage. Thirty female Wistar Albino rats were randomly divided into three groups as control group (n=10), untreated rats; second (RAI) group (n=10), oral radioiodine (111 MBq) administrated rats, and third (ML) group (n=10), oral radioiodine and ML administrated rats. In the third group, ML administration was started 3 days before and ended 10 days after RAI administration. In the third month of radioiodine (RAI) administration, the animals were decapitated and the livers were removed for histopathological examination. The histopathologic data were evaluated comparatively by using Mann Whitney U and Fisher's Exact Tests Differences were determined in all the parameters in terms of intensity between the control and 131 I groups, which showed the harmful effects of 131 I. In the comparison of the 131 I and ML groups, hyperemia was determined respectively 80% to 40%, the presence of inflammatory cells 70% to 60% and capsule thickening 70% to 40%. Montelukast sodium was observed to have a protective effect especially on hyperemia and capsule thickening. According to the study results, radioactive iodine ( 131 I) treatment seems to cause morphological damage to the rat liver, and Montelukast sodium effectively protects the liver against damage.Key words: Iodine-131, histopathology, liver, montelukast sodium, rat. Karaciğerde radyoiodin ( 131 İ) toksisitesine karşı montelukast sodyumun radyoprotektif etkisi: Rat modelinde histopatolojik incelemelerÖzet: Radyoaktif iyot ( 131 I) hipertiroidizm ve tiroid kanserlerinin tanı ve tedavisi amacıyla kullanılan bir radyonükliddir. Montelukast sodyum (Cysteinyl leukotriene receptor-1 inhibitörü) ise antioksidan olarak bilinen bir ilaçtır. Bu çalışma ile rat karaciğerinde radyoiodinden (RAI) kaynaklanan radyasyon hasarına karşı Montelukast sodyumun (ML) radyoprotektif etkisinin histopatolojik olarak değerlendirilmesi amaçlandı. Çalışmada 30 adet dişi Wistar Albino rat kullanıldı ve bunlar rastgele üç gruba ayrıldı; birinci grubu hiçbir işleme tabi tutulmayan kontrol grubu (n=10), ikinci (RAI) grubu, (n=10), oral olarak RAI (111 MBq) uygulanan ratlar, üçüncü (ML) grubunu ise (n=10) oral olarak RAI ve ML uygulanan grup oluşturdu. Üçüncü çalışma grubunda ML uygulaması RAI uygulamasından 3 gün önce başlatıldı ve 10 gün sonra bitirildi. Üçüncü ay sonunda nekropsileri yapılan ratların karaciğer doku örnekleri rutin doku takibine alınarak histopatolojik olarak incelendi. Radyoiodin ve ML grubunda tüm histopatolojik bulgular Mann Whitney U testi ve Fisher'in ekzak test ile karşılaştırılarak değerlendirildi. Bütün ...

Ameliorating effects of N-acetyl cysteine against early liver damage of radioiodine in rats

“…Similarly, intraperitoneal melatonin treatment decreased the tissue advanced the oxidation of protein products and malondialdehyde levels and increase the total sulfhydryl level as well as reducing the early histopathologic damage of the liver after RAIT [34]. Moreover, montelukast had a partial radioprotector effect against the long-term liver damage at the third month of RAIT, particularly in terms of hyperemia and capsule thickening [10]. In the current study, RAIT enhanced oxidative stress in liver tissue by causing an increase in oxidant tissue malondialdehyde levels and a decrease in antioxidant total sulfhydryl levels.…”

“…Vasil'ev et al [8] obtained a moderate decrease in absorptive and secretory hepatocyte function associated with both hypothyroidism and radiation factor in thyroid cancer patients received RAIT. In animal studies, it has been shown that RAIT caused significant morphological damage to rat livers in both short and long-term period of treatment [9,10]. It has been observed that the high dose RAI ablation therapy as 75-150 mCi might lead to drug-induced liver injury (DILI) in the thyroidectomized patient [11].…”